Asian journal of psychiatry

Rules and laws for psychedelics in the US and Europe

Updated

Abstract

Psychedelic drug therapy is being explored for its potential in treating mental health conditions, including depression, PTSD, and anxiety.

  • Psychedelic treatment operates differently from conventional psychiatric methods.
  • Key substances examined include psilocybin, MDMA, mescaline, ketamine, and LSD.
  • Psychedelics are classified as Schedule I substances in the US, indicating potential for misuse.
  • The USFDA is involved in monitoring and expediting the evaluation of psychedelics.
  • Recent FDA guidance supports the safe development of psychedelics for human use.
  • Limited distribution of products like Spravato nasal spray is linked to safety concerns.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free